Iron Refractory Iron Deficiency Anemia in Dizygotic Twins Due to a Novel TMPRSS6 Gene Mutation in Addition to Polymorphisms Associated With High Susceptibility to Develop Ferropenic Anemia

Joana Pinto, MM1, Gustavo Nobre de Jesus, MM2, Mónica Palma Anselmo, MM2, Lúcia Gonçalves, MSc3, Daniela Brás, BSc3, João Madeira Lopes, MD2, João Meneses, MD2, Rui Victorino, MD PhD2, and Paula Faustino, PhD1,3

Abstract
Iron refractory iron deficiency anemia (IRIDA) is an autosomal recessive ferropenic anemia. Its hypochromic microcytic pattern is associated with low transferrin saturation, normal-high ferritin, and inappropriately high hepcidin level. This entity is caused by mutants of the TMPRSS6 gene that encodes the protein matriptase II, which influences hepcidin expression, an iron metabolism counterregulatory protein. We report two 29-year-old dizygotic female twins with ferropenic, hypochromic microcytic anemia with 20 years of evolution, refractory to oral iron therapy. After exclusion of gastrointestinal etiologies, IRIDA diagnosis was suspected and a novel mutation in the TMPRSS6 gene was identified. It was found in intron 11 (c.1396+4 A>T) and seems to affect the gene expression. In addition, 3 polymorphisms already associated with a higher risk of developing iron deficiency anemia were also found (D521D, V736A, and Y739Y). Our case reports an undescribed mutation causing IRIDA and supports the hypothesis that this clinical syndrome may be more common than previously thought and its genetics more heterogeneous than initially described.

Keywords
anemia, refractory, iron, mutation, deficiency

Introduction
Iron deficiency anemia is a common entity, encompassing approximately 50% of all anemia cases worldwide.1 Its etiology is frequently related with blood loss or gastrointestinal malabsorption.2 The increasing number of genetic etiologies related with this anemia such as aceruloplasminemia, ferroportin-1 disease, and haptotransferrinemia requires them to be considered in its differential diagnosis.3 Iron refractory iron deficiency anemia (IRIDA) is a hereditary autosomal recessive anemia. Its hypochromic microcytic pattern is associated with low transferrin saturation, normal-high ferritin, and inappropriately high hepcidin level. Contrastingly, ferritin levels are usually within the normal range or high after therapy. Its designation describes an inadequate response to oral iron therapy and an incomplete response to parenteral iron therapy.4 The disease is caused by mutations in the TMPRSS6 gene that encodes matriptase II, a member of the type II transmembrane serine protease family that is expressed in hepatocytes and regulates hepcidin transcription negatively. This entails the fact that hepcidin levels are inappropriately high in correlation to the low levels of free iron in these patients.5

We present a case of 2 dizygotic twins with IRIDA and a new mutation located in the intron 11 of the TMPRSS6 gene

1Universidade de Lisboa, Lisboa, Portugal
2Hospital de Santa Maria, Lisboa, Portugal
3Instituto Nacional de Saúde Dr. Ricardo Jorge, Lisboa, Portugal

Received January 11, 2017. Revised January 15, 2017. Accepted January 17, 2017.

Corresponding Author:
Joana Pinto, Serviço de Medicina 2A, Hospital de Santa Maria, Avenida Professor Egas Moniz, 1649-035 Lisboa, Portugal.
Email: joana.rsp@gmail.com
(c.1396+4 A>T) that modulates the gene’s splicing in the in silico tests. Additionally, we identified 3 polymorphisms previously associated with a greater risk of developing iron deficiency anemia (SNPs D521D, V736A, and Y739Y).6,7

Case Report

We present two 29-year-old female patients, dizygotic twins. Both have chronic anemia with 20 years of evolution with hemoglobin levels between 8 and 10 g/dL and unresponsive to oral iron therapy. Patient history revealed tiredness with 4 months of evolution, no menstrual disorders or other signs of bleeding abnormalities, and no apparent nutritional deficits. The examination revealed only paleness of the mucosa.

Blood tests revealed anemia with a microcytic and hypochromic pattern and iron deficiency. Laboratory test results are detailed in Table 1. The blood smear revealed anisopikilocytosis and hipocromia. Anti-DS-DNA, ANA, anti-cytoplasm MPO, and PR3 antibodies were negative. Anti-gliadin (IgG and IgA), anti-transglutaminase (IgA), and anti–Helicobacter pylori antibodies were also negative. Hemoglobin A2 and F were normal, and erythroblasts in the peripheral blood were not found. Genetic testing for alpha and beta thalassemia was negative.

Upper endoscopy and colonoscopy did not reveal any macroscopic alterations, and biopsies showed conserved architecture and cellular population in the duodenum, distal colon, and rectum. A light intraepithelial lymphocytic infiltrate of the duodenal mucosa is described without atrophy of the villi.

Genetic studies of the TMPRSS6 gene revealed, in both patients, the presence of heterozygosity of 3 SNPs (single nucleotide polymorphisms), D521D, V736A, and Y739Y, already described associated to higher risk of developing iron deficiency anemia.6,7 In addition to these SNPs, a novel mutation corresponding to a substitution (A>T) in the beginning of intron 11 (c.1396+4 A>T) of the TMPRSS6 gene was also observed. In silico studies (using the Human Splicing Finder software) revealed that this mutation disturbs the intron 11 consensus dador splicing site (wt sequence score = 82.12; mutant sequence score = 73.32; variation −10.72%; MaxEnt −67.34). Consequently, the intron 11 splicing will be affected and the abnormal mRNA will be degraded or translated to a dysfunctional matriptase II protein.

The patients were first submitted to oral iron therapy with 90 mg of ferrous sulfate and 1 mg of folic acid once a day. The evaluation 6 months after revealed remission of the tiredness symptoms. Hemoglobin increased only 0.4 and 0.6 g/dL, respectively. One and a half year after therapy instigation hemoglobin was 1 g/dL higher with concomitant median globular volume and median globular hemoglobin improvement. Serum iron and ferritin also increased but the patients remained anemic.

Discussion

IRIDA is a hereditary autosomal recessive anemia in which mutations in the TMPRSS6 gene, which encodes matriptase II, are responsible for hepcidin levels that are inappropriately high in correlation to the low levels of free iron in these patients.4,5 Until now, 51 families and 74 patients of different ethnic origins have been identified representing a total of 58 different mutations in the TMPRSS6 gene.6 IRIDA’s prevalence is thought to be less than 1:1 000 000,6 although it may be underestimated. In some cases, correlation between genotype and phenotype are yet to be defined.4

We report an IRIDA case where a novel splicing mutation in the TMPRSS6 gene was identified together with 3 gene

Table 1. Twins’ Analytic Evaluation at Presentation and Follow-up With Reference Values.

| Parameter (Reference Range) | Presentation | Follow-up (6 Months) | Follow-up (18 Months) |
|-----------------------------|--------------|----------------------|-----------------------|
|                             | Twin 1       | Twin 2               | Twin 1                | Twin 2                |
| Hb (12.0-15.3 g/dL)         | 9.8          | 8.9                  | 10.2                  | 9.5                   |
| Hct (36.0-46.0%)            | 31.6         | 29.2                 | 32.2                  | 30.0                  |
| MCV (80.0-97.0 fl)          | 68.1         | 64.7                 | 68.0                  | 66.3                  |
| MCH (27.0-33.0 pg)          | 21.1         | 19.7                 | 21.7                  | 20.9                  |
| MCHC (31.5-35.5 g/dL)       | 31.0         | 30.4                 | 31.8                  | 31.5                  |
| RDW (11.5-14.5 CV%)         | 18.1         | 18.5                 | 17.2                  | 17.2                  |
| Iron (50-170 μg/dL)         | 19           | 11                   | —                     | —                     |
| TIBC (250-450 μg/dL)        | 430          | 395                  | —                     | —                     |
| Ferritin (10-291 ng/mL)     | 6            | 7                    | —                     | —                     |
| Vitamin B12 (210-910 pg/mL) | 447          | 524                  | —                     | —                     |
| Folates (>5.4 ng/mL)        | 4.9          | 5.2                  | —                     | —                     |
| Reticulocytes (%)           | 2            | 0.9                  | 4.9                   | 5.2                   |

Abbreviations: Hb, hemoglobin; Hct, hematocrit; MCV, mean corpuscular volume; MCH, mean cell hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; TIBC, total iron building capacity.
SNPs (D521D, V736A, and Y739Y), already described as being associated with a greater risk of developing iron deficiency anemia. Although IRIDA was first described as an autosomal recessive disease caused by 2 different mutations in the TMPRSS6 gene (compound heterozygous state) or 2 copies of the same mutation (homozygous state), there have been increasing reports where this genetic pattern was not encountered but where patients presented with the clinical manifestations and course of IRIDA. In agreement, Nai et al showed that mice with just one TMPRSS6 mutation had greater predisposition for the development of anemia comparatively with mice without any mutations.10

In this case, according to the information obtained during the in silico testing, the location of the novel TMPRSS6 gene mutation affects the gene’s splicing. Consequently, the abnormal mRNA will be degraded or translated into a shorter and nonfunctional matriptase II protein. In addition to this pathogenic mutation, the 2 patients present heterozygosity for 3 SNPs already associated with high risk of developing iron deficiency anemia. The genetic combination of this likely pathogenic mutation with the 3 functional SNPs seems to reduce matriptase II effect to an insufficient level that promotes IRIDA development. Our patients’ unusual TMPRSS6 genotype, the clinical history, and the weak response to oral iron therapy resemble other IRIDA cases. For example, Pellegrino et al demonstrated in a family case study that one TMPRSS6 gene mutation in combination with 2 or more SNPs can clinically present as IRIDA.11

Iron refractory anemia is defined as a weak, slow, and incomplete response to oral iron therapy, with an inadequate improvement of hematological parameters. Although most authors do not attempt a strict definition, Camaschella et al defined iron refractory anemia as an improvement lower than 1 g/dL of hemoglobin after 4 to 6 weeks of therapy with an equivalent of 100 mg/day of elemental iron. Having excluded other causes of iron deficiency, this analytical finding associated with the iron deficiency pattern characteristic of IRIDA (low transferrin saturation, normal-high or normal ferritin, and inappropriately high levels of hepcidin) and family history of IDA should prompt the possibility of this diagnosis. In the cases reported here, after 18 months of oral iron therapy the twins’ hematological parameters did not improve as expected and they remained anemic (hemoglobin 10.7 and 10.5 g/dL) and ferropenic, with low serum iron (16 μg/dL) and ferritin in the lower normal limit (11 ng/mL), confirming the inadequate response to treatment typical of IRIDA patients.

Hepcidin reference values for healthy individuals have not yet been established. Bregman et al reported that hepcidin levels could predict oral iron response in patients with IDA. Hepcidin levels greater than 20 ng/dL represented an 81.6% probability of a nonresponse to oral iron therapy and two thirds of these patients responded to parenteral iron therapy. The fact that IRIDA’s diagnosis can only be confirmed through genetic testing and that hepcidin assay has yet to be standardized led to the decision of not doing such analysis. We acknowledge the possibility that the use of a standardized hepcidin assessment is an indicator of a possible resistance to oral iron therapy.

Currently, parenteral iron is the most viable therapeutic option for IRIDA patients. New intravenous iron formulations (ferric gluconate and iron sucrose) present less adverse effects and a quicker response comparatively to high-molecular-weight iron dextran to which hypersensitivity reactions are frequent. Additionally, parenteral iron can be directly transported to erythropoietic precursors through transporters like transferrin, bypassing the reticuloendothelial system. We conclude that this therapeutic option should be considered regarding its benefits and possible risks in patients with slow and weak response to oral iron therapy. Cau et al presented a case of a 5-year-old female child with a single TMPRSS6 gene mutation refractory to oral iron therapy that responded to oral iron supplemented with ascorbic acid. Although greater evidence of the resourcefulness of this therapy is needed, this alternative might be considered in patients where parenteral iron therapy is contraindicated. Even though recombinant eritropoietin therapy has shown promising results in patients with chronic anemia, it did not increase hemoglobin levels or hepcidin clearance in patients with IRIDA.18

In our case, IRIDA was suspected after an inadequate response to oral iron therapy. This highlights the necessity of establishing universally accepted criteria for an inadequate response to oral iron therapy. This case also supports the hypothesis that the clinical syndrome that accompanies IRIDA might be more common than previously thought and its genetics more heterogeneous than initially described. We agree with other authors’ views that IRIDA should be more widely considered in the differential diagnosis of iron deficiency anemia. Moreover, hepcidin routine measurement can also be helpful for the differential diagnosis between iron deficiency anemia and IRIDA. Nevertheless, TMPRSS6 genetic study remains crucial, enabling not only IRIDA’s definitive diagnosis but also further characterizing the disease’s genetic and clinical correlation.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

References
1. World Health Organization. Worldwide prevalence of anaemia. *WHO Rep.* 2005;51. doi:10.1017/S1368980008002401.
2. De Falco L, Sanchez M, Silvestri L, et al. Iron refractory iron deficiency anemia. *Haematologica.* 2013;98:845-853. doi:10.1002/humu.22632.
3. Archer NM, Brugnara C. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci. 2015;52:256-272. doi:10.3109/10408365.2015.1038744.
4. De Falco L, Silvestri L, Kannengiesser C, et al. Functional and clinical impact of novel TMPRSS6 variants in iron-refractory iron-deficiency anemia patients and genotype-phenotype studies. Hum Mutat. 2014;35:1321-1329. doi:10.1002/humu.22632.
5. Yilmaz Keskin E, Yenicesu I. Iron-refractory iron deficiency anemia. Turk J Hematol. 2015;32:1-14. doi:10.4274/tjh.2014.0288.
6. Poggiali E, Andreozzi F, Nava I, Consonni D, Graziadei G, Cappellini MD. The role of TMPRSS6 polymorphisms in iron deficiency anemia partially responsive to oral iron treatment. Am J Hematol. 2015;90:306-309. doi:10.1002/ajh.23929.
7. Wang CY, Meynard D, Lin HY. The role of TMPRSS6/matrilysin-2 in iron regulation and anemia. Front Pharmacol. 2014;5:114. doi:10.3389/fphar.2014.00114.
8. Xiong Y, Wu Z, Yang W, et al. A novel splicing mutation of TMPRSS6 in a Chinese child with iron-refractory iron deficiency anemia. Br J Haematol. 2015;171:2012-2014. doi:10.1111/bjh.13416.
9. Finberg KE, Heeney MM, Campagna DR, et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia (IRIDA). Nat Genet. 2008;40:569-571. doi:10.1038/ng.1130.
10. Nai A, Pagani A, Silvestri L, Camaschella C. Increased susceptibility to iron deficiency of Tmprss6-haploinsufficient mice. Blood. 2010;116:851-852.
11. Pellegrino RM, Coutinho M, D’Ascola D, et al. Two novel mutations in the tmprs6 gene associated with iron-refractory iron-deficiency anaemia (IRIDA) and partial expression in the heterozygous form. Br J Haematol. 2012;158:666-668. doi:10.1111/j.1365-2141.2012.09198.x.
12. Heeney MM, Finberg KE. Iron-refractory iron deficiency anemia (IRIDA). Hematol Oncol Clin North Am. 2014;28:637-652. doi:10.1016/j.hoc.2014.04.009.
13. Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372:1832-1843. doi:10.1056/NEJMra1401038.
14. Hershko C, Camaschella C. How I treat unexplained refractory iron deficiency anemia. Blood. 2014;123:326-333. doi:10.1182/blood-2013-10-512624.
15. Bregman DB, Morris D, Koch TA, He A, Goodnough LT. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol. 2013;88:97-101. doi:10.1002/ajh.23354.
16. Bregman DB, Goodnough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia. Ther Adv Hematol. 2014;5:48-60. doi:10.1177/2040620714521127.
17. Cau M, Galanello R, Giagu N, Melis MA. Responsiveness to oral iron and ascorbic acid in a patient with IRIDA. Blood Cells Mol Dis. 2012;48:121-123. doi:10.1016/j.bcmd.2011.11.007.
18. Lehmburg K, Grosse R, Muckenthaler MU, et al. Administration of recombinant erythropoietin alone does not improve the phenotype in iron refractory iron deficiency anemia patients. Ann Hematol. 2013;92:387-394. doi:10.1007/s00277-012-1618-8.
19. Kodama K, Noguchi A, Adachi H, Hiebiguchi M, Yano M, Takahashi T. Novel mutation in the TMPRSS6 gene with iron-refractory iron deficiency anemia. Pediatr Int. 2014;56:e41-e44. doi:10.1111/ped.12395.